References
- 1. Steenkamp ET, Wingfield MJ, McTaggart AR, Wingfield BD. Fungal species and their boundaries matter – Definitions, mechanisms and practical implications. Fungal Biol Rev. 2018 Mar 1;32(2):104–16. DOI: 10.1016/j.fbr.2017.11.00210.1016/j.fbr.2017.11.002
- 2. Man A, Ciurea CN, Pasaroiu D, Savin A-I, Toma F, Sular F, et al. New perspectives on the nutritional factors influencing growth rate of Candida albicans in diabetics. An in vitro study. Mem Inst Oswaldo Cruz. 2017 Sep;112(9):587–92. DOI: 10.1590/0074-0276017009810.1590/0074-02760170098557244328902283
- 3. Ciurea CN, Mare A, Man A. The influence of metformin on Candida albicans growth and germ tube formation. 11th edition of the ASKLEPIOS International Congress for Students and Young Physicians, Sibiu, Romania. Abstract book ISSN 1843-0406. 2018:197.
- 4. Monea A, Santacroce L, Marrelli M, Man A. Oral candidiasis and inflammatory response; A potential synergic contribution to the onset of Type-2 Diabetes Mellitus. Australasian Med J. 2017;10(6):550-556. DOI: 10.21767/AMJ.2017.305310.21767/AMJ.2017.3053
- 5. Petrovan C, Bereczki-Temistocle DL, Man A. Candida in Oral and Maxillofacial Pathology: Clinical Findings and Risk Factors. J Interdiscip Med. 2017 Mar 1;2(s1):36–42. DOI: 10.1515/jim-2017-001310.1515/jim-2017-0013
- 6. Rosca I, Bostanaru AC, Minea B, Nastasa V, Gherghel I, Panzaru CV, et al. Candida albicans isolates from Romanian patients. Rev Romana Med Lab. 2018 Jul 6;26(aop). DOI: 10.2478/rrlm-2018-002310.2478/rrlm-2018-0023
- 7. Zain ME. Impact of mycotoxins on humans and animals. J Saudi Chem Soc. 2011 Apr 1;15(2):129–44. DOI: 10.1016/j.jscs.2010.06.00610.1016/j.jscs.2010.06.006
- 8. Bennett JW, Klich M. Mycotoxins. Clin Microbiol Rev. 2003 Jul;16(3):497–516. DOI: 10.1128/CMR.16.3.497-516.200310.1128/CMR.16.3.497-516.200316422012857779
- 9. Man A, Mare A, Toma F, Curticăpean A, Santacroce L. Health Threats from Contamination of Spices Commercialized in Romania: Risks of Fungal and Bacterial Infections. Endocr Metab Immune Disord Drug Targets. 2016;16(3):197–204. DOI: 10.2174/187153031666616082314581710.2174/187153031666616082314581727552982
- 10. Agrosoaie R, Streinu-Cercel A, Azoicai D, Bejan C, Dorobat O, Mihai A, et al. Epidemiological data and antifungal susceptibility in invasive fungal infections - a Romanian infectious diseases tertiary hospital’s experience. Preliminary report. Rev Romana Med Lab. 2017 Aug 21;25(4):345–53. DOI: 10.1515/rrlm-2017-002310.1515/rrlm-2017-0023
- 11. Földes A, Bilca D-V, Székely E, Enikő F, Toma F. Involvement of yeast species in fungaemia – an investigation of clinical data. Rev Romana Med Lab. 2008;13(4):49–58.
- 12. Minea B, Nastasa V, Moraru RF, Kolecka A, Flonta MM, Marincu I, et al. Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2015 Feb;34(2):367–83. DOI: 10.1007/s10096-014-2240-610.1007/s10096-014-2240-625224578